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Vitamin E deficiency is associated with many neurological problems. Although the mechanisms of vitamin E action in 
neurodegenerative diseases are not clear, there are many possible mechanisms. Examples of such mechanisms are the 
protective effects of vitamin E against oxidative stress damage and its suppressive role in the expression of many genes involved 
in the development of neurodegeneration. Many studies have evaluated the relationship between vitamin E intake or vitamin 
E levels in body fluids and neurodegenerative diseases. Some studies concluded that vitamin E can play a protective role in 
neurodegeneration with respect to diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke and amyotrophic 
lateral sclerosis (ALS). Vitamin E supplementation was also associated with risk factors for some neurodegenerative diseases. 
In this review, we discuss the possible effects of vitamin E on the development and course of AD, PD, stroke and ALS, and the 
potential mechanisms involved. 
Key words: vitamin E, oxidative stress, neurodegeneration, Alzheimer’s disease, Parkinson’s disease
INTRODUCTION 
Characterized by specific neuronal cell losses, neu‑
rodegenerative diseases are among the leading cause of 
disabilities in elderly people (Knight, 1997; Floyd and 
Hensley 2002, Ricciarelli et al., 2007). Oxidative stress 
has important roles in the pathogenesis of neurodegen‑
erative diseases. It is known that oxidative stress lev‑
els in the brain increase with age (Floyd and Hensley, 
2002). Oxidative stress occurs due to the presence of 
free radicals in high amounts and/or insufficient levels 
of antioxidants (Tu and Weissman, 2004). 
Reactive oxygen species (ROS) cause cell damage by 
means of lipid peroxidation and oxidation of proteins 
and DNA (Halliwell, 1999). Therefore, cells have devel‑
oped various defense and repair mechanisms in order 
to cope with oxidative stress. Antioxidants such as vi‑
tamin E play important roles in these defense mech‑
anisms (Halliwell, 1999; Ricciarelli et al., 2007). In ad‑
dition, vitamin E is the main lipophilic antioxidant in 
the brain by concentration (Kontush and Schekatolina, 
2004). Vitamin E is effective in the neutralization of un‑
stable lipid peroxide radicals produced from polyunsat‑
urated fatty acids (Burton and Traber, 1990; Traber et 
al., 1990; Ulatowski and Manor, 2015). It is believed that 
vitamin E, through these mechanisms, may have ther‑
apeutic effects in many neurodegenerative diseases in‑
cluding Alzheimer’s disease (AD), Parkinson’s disease 
(PD), stroke and amyotrophic lateral sclerosis (ALS) as 
illustrated in Fig. 1 (Sung et al., 2004; Ascherio et al., 
2005; Ricciarelli et al., 2007). 
There is a large number of studies in the literature 
evaluating the correlation between the level of vita‑
min E in the serum and cerebrospinal fluid, and AD, 
PD, stroke and ALS (Fernandez‑Calle et al., 1992; Graf 
et al., 2005). However, results of these studies are con‑
tradictory (Fernandez‑Calle et al., 1992; Paraskevas et 
al., 2003). Another important research area is the role 
of vitamin E supplementation. Some studies indicate 
that vitamin E supplementation has protective roles 
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in these neurodegenerative diseases, while several 
others could not find such an effect (Scheider et al., 
1997; Miyake et al., 2011; Hughes et al., 2016; Yang et 
al., 2017). 
This review focuses on the potential effects and 
mechanisms of vitamin E action in AD, PD, stroke and 
ALS.
Oxidative stress and neurodegenerative diseases 
Approximately 50% of the brain’s dry weight is 
made up of lipids (Behl, 1999). The myelin sheath is 
characterized by 75–80% lipids and membranes and 
neurons are rich in poly‑unsaturated fatty acids 
(Poitelon et al., 2020). Therefore, the central nervous 
system (CNS) is prone to oxidation (Behl, 1999). It is 
known that oxidative stress has a key role in AD, PD, 
ALS, stroke and other age‑related diseases (Behl, 1999; 
Abou‑Sleiman et al., 2006). The effects of the protec‑
tive antioxidant system deteriorates with age (Behl, 
1999). Additionally, cell membranes become more 
vulnerable to oxidation with age. Oxidation general‑
ly targets lipids (cholesterol, poly‑unsaturated fatty 
acids), proteins and nucleic acids (Grimm et al., 2016; 
Cheignon et al., 2017). It is believed that increased ox‑
idative stress, abnormal mitochondrial function and 
excitotoxicity are the most probable mechanisms be‑
hind neurodegeneration, even though the causes of 
AD, PD, ALS and stroke have not been fully explained 
(Behl, 1999; Abou‑Sleiman et al., 2006). In addition, 
it is believed that oxidative stress may increase the 
risk of progression of neurodegenerative diseases 
by causing abnormal protein folding and function 
(Bossy‑Wetzel et al., 2004; Ricciarelli et al., 2007). 
Ischemia triggers processes that increase free rad‑
ical formation through different pathways. Firstly, 
glutamate, which activates the N‑methyl‑D‑aspartate 
(NMDA) receptor and other ionotropic receptors, is re‑
leased in massive amounts from neurons and glia. Isch‑
emia also causes an increase in intracellular Ca2+ con‑
centrations, leading to excessive activation of prote‑
ases, lipases, nucleases and protein kinases, as well as 
increases in nitric oxide synthases (NOS) (Cherubini et 
al., 2008). This process is called excitotoxicity. As a re‑
sult, these enzymes damage cellular and extracellular 
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Fig. 1. Mechanisms and effects of vitamin E on neurodegenerative diseases. The protective effects of vitamin E against lipid peroxidation, oxidative damage 
and toxic oxidation are similar in PD, AD and ALS. * This symbol represents mechanisms. # This symbol represents effects.
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structures and kill neurons by increasing ROS forma‑
tion following nitric oxide release (Rodríguez‑Lara et 
al., 2016). Additionally, excitotoxicity events increase 
the expression of phospholipase A2 and cyclooxygen‑
ase (COX), which directly produce oxygen free radicals. 
Oxidative stress also increases due to the influx of in‑
flammatory cells such as neutrophils, monocytes and 
macrophages during reperfusion. These cells secrete 
immune mediators such as TNF‑α and IL‑1β, which in‑
crease the expression of pro‑inflammatory genes and 
production of ROS (Cherubini et al., 2008). 
Amyloid β formation is related to oxidation and 
inflammation. Amyloid β is believed to cause potas‑
sium efflux from neurons, which can activate inflam‑
masomes and IL‑1β secretion (Salminen et al., 2009). 
This increases oxidative stress, which causes the gen‑
eration of ROS. These events further upregulate the 
generation of amyloid β plaques and increase phos‑
phorylation of the tau protein through various mech‑
anisms (Cassidy et al., 2020). 
Vitamin E and neurodegenerative diseases: 
mechanisms and actions 
There are eight forms of vitamin E (α‑, β‑, γ‑, δ‑to‑
copherol, and α‑, β‑, γ‑, δ‑tocotrienol), all of which are 
fat‑soluble compounds that are synthesized in plants. 
α‑tocopherol, the most common form of vitamin E in 
human tissues, has long been considered as a cyto‑
protective factor with suggested roles in preventing 
oxidation, as well as inflammatory and degenerative 
processes (Galli et al., 2017). First described in 1922 
by Evans and Bishop as a dietary factor essential to 
prevent fetal reabsorption in rats (Evans et al., 1922), 
vitamin E was soon after identified as an antioxidant 
of polyunsaturated lipids (Galli et al., 2017).
A number of studies have pointed to the import‑
ant effects of vitamin E in promoting health. Firstly, 
genetic vitamin E deficiency causes many neurolog‑
ical problems (Joshi and Praticò, 2012). This type of 
deficiency is triggered by mutations in the TTPA gene 
which encodes the tocopherol transfer protein (TTP). 
This results in a condition called ataxia with vitamin 
E deficiency (AVED), which is characterized by diffi‑
culty coordinating movement (ataxia), aphasia, loss 
of reflexes and numbness as some of its symptoms 
(Schuelke, 2016). The biological half‑life of vitamin 
E in the brain is very short, which makes the brain 
particularly sensitive to its deficiency. In addition, 
expression levels of mutations in TTPA are marked‑
ly elevated in brain samples from human patients af‑
flicted with oxidative stress‑related neurodegenera‑
tive diseases such as AVED and AD. Taken together, 
these findings demonstrate that vitamin E and TTPA 
may have critical roles in neurodegenerative diseases 
(Joshi and Praticò, 2012; Ulatowski and Manor, 2015). 
As a lipid‑soluble, chain‑breaking antioxidant, vi‑
tamin E plays a key role in maintaining the integrity 
of cellular membranes by protecting them against ox‑
idative stress caused by the peroxidation of polyun‑
saturated fatty acids (Ricciarelli et al., 2007; Lee and 
Ulatowski, 2019). With its chain‑breaking antioxidant 
function, vitamin E also has both a protective and cu‑
rative effect on cellular membranes in the CNS (Joshi 
and Praticò, 2012). Given these functions, there is good 
indication that vitamin E may have a unique, original 
and special role in neurological diseases (Ulatowski and 
Manor, 2015). 
Antioxidant vitamins protect cells against oxida‑
tive damage by neutralizing the effects of ROS (Ricc‑
iarelli et al., 2007). Vitamin E is one of the strongest 
dietary antioxidants which protects proteins, lipids 
and nucleic acids from oxidation as it is an oxygen 
radical scavenger (Niki et al., 1989; Fariss and Zhang, 
2003). It has been shown that application of vitamin E 
to cell membranes protects the cells from toxic oxida‑
tion (Fariss, 1997; Fariss and Zhang 2003). 
The antioxidant properties of tocopherols regu‑
late oxidative damage; however, vitamin E also shows 
non‑antioxidant features that regulate cell signaling 
and inflammation (Cook‑Mills and McCary, 2010). The 
anti‑inflammatory activity of vitamin E, as well as its 
antioxidant features, may together confer it a neuro‑
protective role (Ricciarelli et al., 2007). Since chronic 
inflammation is associated with neurodegenerative 
diseases (McGeer and McGeer, 2001), it is important to 
understand how vitamin E inhibits inflammation. The 
anti‑inflammatory role of vitamin E does not seem to 
be related to its antioxidant activity. Several molec‑
ular mechanisms are involved in the anti‑inflamma‑
tory effects of vitamin E (Reiter et al., 2007). Among 
others, it has been shown that vitamin E supplemen‑
tation reduces the production of prostaglandin E2, 
which is a mediator of inflammation. This is caused 
by inhibiting the enzymatic activity of cyclooxygen‑
ase 2 (COX‑2), which is a rate limiting enzyme in‑
volved in the conversion of arachidonic acid to pros‑
taglandins (Lewis et al., 2019). Tocotrienols downreg‑
ulate Src, mitogen activated protein kinases (MAPKs) 
and extracellular signal‑regulated kinases (ERKs) in 
neurons. In addition, α‑tocotrienol and α‑tocopherol 
bind to 5‑lipoxygenase (5‑Lox) to inhibit it indepen‑
dent of its antioxidant activity. Since 5‑Lox and sig‑
naling through the Src/MAPK/ERK pathways play an 
important role in inflammatory responses, tocotrie‑
nols may influence inflammation by inhibiting their 
activities (Cook‑Mills and McCary, 2010). 
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Multi‑effects and mechanisms of vitamin E action 
in Alzheimer’s disease 
Alzheimer’s disease 
AD is the most prevalent form of dementia among 
neurodegenerative diseases. It is clinically character‑
ized by the loss of memory and consciousness (Alzhei‑
mer’s Association, 2015). More than 47 million people 
live with dementia worldwide and this number is ex‑
pected to exceed 131 million in 2050 (Prince et al., 2016). 
AD is characterized by the accumulation of amyloid 
beta (β) peptides in the extracellular space of neurons, 
as well as the formation of intracellular neurofibril‑
lary tangles caused by the hyperphosphorylation of 
tau proteins. Extracellular deposits of amyloid β form 
senile plaques, which is a physiological feature com‑
monly associated with AD. Amyloid precursor protein 
(APP), presenilin 1 (PSEN1), presenilin 2 (PSEN2) and 
apolipoprotein E (APOE) are associated with AD. Mu‑
tations in APP, PSEN1 and PSEN2 cause early‑onset AD, 
which constitutes 5% of all cases. Mutations in APOE do 
not cause late‑onset disease directly, but dramatically 
increase the occurrence of the disease in people over 65 
(Wang and Ding, 2008). 
APP is a transmembrane glycoprotein that consists 
of 700 amino acids and is expressed by neurons of the 
CNS. Although its role is not completely known, it is 
believed that APP is vital for brain development, syn‑
apse plasticity and memory. APP is broken down by α‑, 
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Fig. 2. The role of oxidative stress on neurodegenerative diseases.
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β‑ and ɣ‑secretase enzymes and this transformation 
produces insoluble 39–43 kDa peptide fragments. It is 
known that among the amyloid β fragments, isopho‑
rone has cytotoxic effects that accelerate oxyradical 
formation and causes neurodegeneration (dos Santos 
Picanco et al., 2016). 
Neurofibrillary tangles are the second most import‑
ant indicator of AD. Hyperphosphorylated tau proteins 
are the most significant components of neurofibrillary 
tangles. Phosphorylated tau accumulates in neurons 
during AD. Phosphorylated tau loses its normal func‑
tion stepwise and compounds microtubules, before 
coming to a stable state that is prone to aggregation 
(Xia and Mo, 2016). 
Biosynthesis of cholesterol and an increase in cho‑
lesterol levels are correlated with an increase of pro‑
teolysis mediated by β‑ and γ‑secretase enzymes (Chin 
and Tay, 2018). This relationship was confirmed in an‑
imal studies, as it has been shown that amyloid plaque 
formation increases in rats fed a high cholesterol diet 
(Refolo et al., 2000). 
Glutamate dysfunction is an important potential 
mechanism in the etiology of AD. Glutamate is a key 
excitatory neurotransmitter in the CNS, playing an im‑
portant role in memory formation and learning (Esposi‑
to et al., 2013). The accumulation of excess amounts of 
glutamate in the brain leads to the hyperactivation of 
the glutamate‑N‑methyl‑D‑aspartate (NMDA) receptor, 
which leads to excitotoxicity due to intracellular cal‑
cium overload, resulting in cell death. This is a poten‑
tial mechanism underlying neurodegeneration in AD). 
Amyloid β formation affects glutamate accumulation, 
which increases NMDA receptor activity. Activation of 
the NMDA receptors in turn increases amyloid β pro‑
duction, creating a positive feedback loop (Wang and 
Reddy, 2017; Chin and Tay, 2018). In addition, consti‑
tutive activation of this pathway also increases phos‑
phorylation of the tau protein, which causes the desta‑
bilization of microtubules, leading to synapse loss and 
neuronal death (Esposito et al., 2013). 
Potential mechanism of vitamin E in Alzheimer’s disease 
Amyloid β accumulation in AD increases free radi‑
cal formation, and also indirectly causes the formation 
of pro‑oxidants by stimulating inflammatory cells. It is 
thought that vitamin E may contribute to protection 
against lipid peroxidation in the brain thanks to its an‑
tioxidant activity. For example, in neuronal cultures, 
vitamin E has been shown to inhibit the formation of 
amyloid β‑related ROS and lead to decreased indicators 
of oxidative stress (Yatin et al., 2000). 
It is also known that inflammatory pathways are im‑
portant in the pathogenesis of AD. It has been observed 
that there are increased levels of the pro‑inflammatory 
cytokines IL‑1β, IL‑6 and TNFα in both the brain and 
cerebrospinal fluid in AD. It has also been found that 
both TNFα and IL‑1β increase levels of APP and amy‑
loid β peptides (Heppner et al., 2015). Prostaglandins 
and free radicals are secreted by microglia astrocytes 
and resident macrophages in the CNS are present in in‑
creased numbers around senile plaques (Stuchbury and 
Münch, 2005). Prolonged microglia activation leads to 
the release of pro‑inflammatory cytokines, which ini‑
tiates a pro‑inflammatory cascade and subsequently 
contributes to neuronal damage and loss (Wang et al., 
2015). For example, overexpression of TNF‑α can lead 
to increased amyloid β levels and reduce its clearance, 
which increases neuronal loss, leading to cognitive 
decline that includes learning and memory deficits in 
AD (Tobinick, 2009). An inhibitor of TNF‑α synthesis 
suppresses amyloid β‑induced activation of microglia, 
neuronal degeneration, memory dysfunction, and at‑
tenuates inflammation markers in the setting of neu‑
roinflammation and AD (Zhang and Jiang, 2015). The 
inflammatory process itself leads to amyloid β aggre‑
gation, tau formation, synaptic damage, neuronal loss 
and the activation of other inflammatory participants 
(Wang et al., 2015). In addition, several studies suggest 
that pro‑inflammatory cytokines in the CNS cross the 
blood‑brain barrier and can contribute to cognitive de‑
cline in AD patients (Perry et al., 2007; Holmes et al., 
2009). Increasing evidence therefore shows that in‑
flammation plays a key role in AD pathogenesis. 
Mitochondria are uniquely poised to play a pivot‑
al role in both survival and death pathways in neurons 
because they are regulators of energy metabolism and 
apoptosis (Moreira et al., 2006). The dysfunction of pro‑
teins involved in electron transport in the mitochondria 
has been associated with the pathophysiology of AD 
(Blass and Gibson, 1991), as well as in PD and ALS (Hi‑
rai et al., 2001). Mitochondrial dysfunction plays an im‑
portant role in the pathogenesis of AD as it decreases 
the formation of adenosine triphosphate (ATP) and in‑
creases the production of ROS. Impaired mitochondria 
lose the capacity to buffer Ca2+ and also release several 
pro‑apoptotic factors, leading to apoptosis. Altogether, 
mitochondrial alterations contribute to AD pathogenesis 
(Moreira et al., 2010). 
Oligomerization of amyloid β, which has an import‑
ant role in AD, induces phosphorylation of p38 MAPK 
through increased oxidative stress. p38 also induces the 
hyperphosphorylation of tau proteins, which are in‑
volved in AD pathogenesis. Vitamin E inhibits activation 
of p38 by hindering oxidative stress, and thus prevents 
phosphorylation of tau proteins (Giraldo et al., 2014). 
It has been found that vitamin E supplementation pre‑
vents p38 activation. At the same time, vitamin E inhib‑
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its RCAN1, a calcineurin negative regulator, which causes 
dephosphorylation of tau protein (Giraldo et al., 2014). 
The relationship between AD and vitamin E has 
been studied in a number of ways, some of which in‑
clude evaluation of levels of plasma and serum vitamin 
E equivalents in AD and healthy subjects, vitamin E sup‑
plementation and dietary intake, as well as effects of 
the vitamin at the cellular level. Table I shows studies 
that examined serum and/or plasma levels of vitamin 
E, Table II shows the studies that looked at vitamin E 
supplementations, Table III includes studies on dietary 
vitamin E intake and Table IV shows in vitro cell culture 
studies. These studies show that vitamin E levels in the 
sera of individuals with AD are very low, and that high‑
er levels of vitamin E decrease AD risk. It has also been 
observed that dietary intake of vitamin E generally de‑
creases AD progression, and that vitamin E acts as a pro‑
tector, especially in individuals with a low risk of AD. 
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Table I. Studies evaluating serum and/or plasma vitamin E levels in Alzheimer’s disease (AD).
References Purpose and study population Analysis method Conclusion
Guan  
et al.  
 
To evaluate the effects of vitamin E 
supplementation on oxidative stress 
biomarkers in individuals with and 
without AD.
Vitamin E levels were 
measured with HPLC. 
 
Use of 400 mg/day of vitamin E for six months 
significantly decreased urinary 8‑iso‑PGF2 levels (p<0.05). 
It was suggested that oxidative stress (8‑iso‑PGF2) in AD 
was eliminated by the antioxidant effect of vitamin E.
Mangialasche 




Evaluation of the correlation between 
all forms of plasma vitamin E and 
mild cognitive impairment and AD; 
168 individuals with AD, 166 with mild 
cognitive impairment and 187 healthy 
individuals.
•  α‑tocopherol quinone (TQ)
•  5‑NO2‑γ‑tocopherol
•  All tocopherols
All tocotrienols Measured 
with HPLC. 
Tocopherol, tocotrienol and total vitamin E levels in 
individuals with AD and mild cognitive impairment were 
found to be lower than those in healthy individuals. 
Both diseases were found to be correlated with vitamin E 
damage levels. 
Mangialasche 




Evaluation of the effects of all plasma 
vitamin E forms on AD; 232 individuals 
over the age of 80. 
 
 
α‑, β‑, γ‑ and δ‑tocopherol 




It was found that individuals whose plasma levels of 
total tocotrienol, tocopherol and vitamin E were in the 
3rd tertile had a higher risk of AD progression. It was 
also observed that while α‑tocopherol is effective in 
inhibiting disease progression, the β form is generally 
the most effective.
Table II. Studies on vitamin E supplementation in Alzheimer’s disease (AD).
References Population Source of vitamin E Conclusion
Wang  
et al. 




It was found that oxidative stress and amyloid β oligomers 
decreased. IL‑6 and IL‑1 production was inhibited.
Sinha  
et al.  
The study was conducted in 4–6 month 
and 22–24 month‑old rats. 
1.5 mg/100 g  
(body weight) 
α‑tocopherol




769 individuals with mild cognitive 
impairment.
2,000 IU vitamin E 
supplementation




613 individuals with mild and medium 
range cognitive impairment. 
2,000 IU α‑tocopherol/
day supplementation 
was given for five years.




3,786 individuals over the age of 60. 400 IU/day vitamin E 
(six years)
It was found that vitamin E has no effect on dementia, 
a primary cause of AD.
Table III. Studies on dietary vitamin E intake in Alzheimer’s disease (AD).
References Population Vitamin E evaluation method Conclusion
Morris  
et al. 
3,718 individuals over 
the age of 65.
Vitamin E intake levels were 
evaluated with Harvard BTS.
It was observed that all tocopherol levels (not only α‑tocopherol) 
have a protective effect against AD progression risk.
Devore  
et al. 
5,395 individuals over 
the age of 55.
Vitamin E intake levels were 
evaluated with BTS (9.6 years 
of follow‑up, on average)
Dementia progression risk was found to be lower in individuals 
with higher dietary vitamin E intake in the beginning. Individuals 
whose vitamin E intake levels are in the 3rd tertile have 25% less 
risk than the ones in the 1st tertile (AD).
Moris  
et al.  
815 individuals over 
the age of 65. 
Vitamin E intake levels 
were evaluated with BTS 
(for 3.9 years on average).
Vitamin E had a protective effect against AD in individuals whose 
apo e4 allele (AD risk factor) was negative. 
Laurin  
et al. 
2,459 male individuals 
45–68 years of age. 
Vitamin E intake levels were 
evaluated by means of a 24‑hour 
food consumption record.
Midlife vitamin E intake was not found to be correlated with 
late‑life dementia and/or Alzheimer’s risk. 
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Multi‑effects and mechanisms of vitamin E  
on Parkinson’s disease 
Parkinson’s disease 
PD is the second most common neurodegenera‑
tive disease which affects 6 million people worldwide 
(Lesage and Brice, 2009; Bhimani, 2014). PD is charac‑
terized by rigidity and shaking which affect mobility, 
real‑like dreams and hallucinations affecting sleep 
quality, confusion and depression (Carter et al., 2008; 
Pretzer‐Aboff et al., 2009). In PD, patients suffer from 
pathological loss of dopaminergic neurons in the sub‑
stantia nigra pars compacta in the midbrain. The loss 
is responsible for motor symptoms of the disease (Ji‑
ang and Dickson, 2018). 
Data in the literature shows that brains of PD pa‑
tients have low levels of endogenous antioxidants (glu‑
tathione and co‑enzyme Q10), increased dopamine oxi‑
dation and high iron levels (Lan and Jiang, 1997; Götz et 
al., 2000; Sutachan et al., 2012). Oxidative metabolism 
of dopamine causes the formation of highly cytotoxic 
hydroxyl radicals, by producing peroxides which react 
with ferrous iron (Olanow, 2003). It was also reported 
that lipoprotein oxidation increases in the substantia 
nigra of PD patients (Dexter et al., 1994). In PD patients, 
increased oxidative stress is correlated with the degen‑
eration of dopaminergic neurons (Lv et al., 2015). In 
addition to these mechanisms, one of the possible risk 
factors underlying PD are genetic variants (Wüst et al., 
2016). To date, molecular genetic analyses have identi‑
fied over 500 distinct DNA variants in five disease genes 
associated with familial PD; α‐synuclein (SNCA), parkin 
(PARK2), PTEN‐induced putative kinase 1 (PINK1), DJ‐1 
(PARK7) and Leucine‐rich repeat kinase 2 (LRRK2) (Nuy‑
temans et al., 2010). By phosphorylating PARKIN, PINK1 
regulates the turnover of damaged mitochondria (Lo‑
pez‑Fabuel et al., 2017). In addition, the presenilin‑as‑
sociated rhomboid‑like (PARL) protein, a serine pro‑
tease located in the inner mitochondrial membrane, 
interacts with and processes PINK1 (Wüst et al., 2016). 
Vitamin E in Parkinson’s disease 
Polymorphisms in the microtubule‐associated pro‑
tein tau (MAPT) gene are associated with an increased 
risk of PD, and MAPT methylation is negatively asso‑
ciated with MAPT expression (Coupland et al., 2014). 
Vitamin E decreases MAPT expression by increasing 
MAPT gene methylation and it may decrease PD risk 
(Coupland et al., 2014). Vitamin E is thus regarded as 
a neuroprotective agent against PD due to these effects 
(Sies et al., 1992). 
There is a large number of in vitro animal and human 
studies that have evaluated the correlation between vi‑
tamin E and PD (Table V). These studies examined the 
effect of dietary vitamin E intake, supplementation at 
high doses and serum levels of vitamin E on PD. These 
studies showed that vitamin E supplementation may 
generally decrease PD risk, but there was no correla‑
tion between vitamin E levels in serum or cerebrospi‑
nal fluid and PD. Studies evaluating the effects of di‑
etary vitamin E intake on PD have conflicting results 
(Scheider et al., 1997; Miyake et al., 2011; Hughes et al., 
2016; Yang et al., 2017). In light of this data, vitamin E 
supplementation can be considered to prevent PD and/
or ameliorate its prognosis. However, more studies are 
required to determine a therapeutic dose for routine 
application. 
Multiple effects and mechanisms of vitamin E  
on stroke 
Stroke is among the top reasons of death in the world 
and is also the most common reason of permanent dis‑
ability. Ischemic strokes make up 87% of all stroke cas‑
es, occurring when there is a disruption in the blood 
flow from the artery that supplies the brain with blood 
rich in oxygen. Hemorrhagic stroke is another type of 
condition which occurs when blood begins to leak from 
an artery in the brain. Brain cells are suppressed and 
damaged due to the leaking blood. Temporary ischemic 
attack is characterized with neurological dysfunction 
resulting from decreasing blood flow in the brain with‑
out a permanent brain damage (Centers for Disease 
Control and Prevention, 2018). 
High blood pressure, diabetes mellitus, arrhyth‑
mia, hyperlipidemia, smoking, sedentary lifestyle 
and bad nutritional habits are among the risk factors 
of stroke. It is known that decreasing blood pres‑
sure protects people from the adverse outcomes of 
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Evaluation of the effects of different α‑tocopherol 
forms on amyloid β formation in neuron culture
Amyloid β levels increased after exposure to all tocopherol forms.
Tocopherols also increased formation of β and γ secretases.
Ayasolla  
et al. 
Evaluation of the effect of vitamin E on 
Alzheimer‑related indicators in rat astrocytes.
TNF‑α, IL‑1H levels, which increase inducible NOS (iNOS) expression, 
were suppressed with vitamin E.
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stroke, while diabetes increases stroke risk at every 
age. Atrial fibrillation, or arrhythmia, increases the 
risk of stroke by five times (Wolf et al., 1987). It has 
been found that the risk of stroke is approximately 
two times higher among smokers than non‑smok‑
ers. As the daily number of cigarettes rises, the risk 
of stroke increases (Soares‑Miranda et al., 2015; 
Markidan et al., 2018). Inadequate physical activity is 
also correlated with high risk of stroke (Soares‑Mi‑
randa et al., 2015). Nutrition also plays a major role in 
stroke as it does in all cardiovascular diseases (Benja‑
min et al., 2018). For example, the Mediterranean diet 
is correlated with a low risk of hemorrhagic stroke 
(Tektonidis et al., 2015). 
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Table V. Effects of dietary or vitamin E supplementation on serum vitamin E levels in Parkinson’s disease (PD).
References n Study focus Study design Conclusion
Pasbakhsh 
et al.
40 rats Vitamin E and PD 24 IU/kg vitamin E 
supplementation.
Protective effect on the locus coeruleus 
neurons in Parkinson’s patients.
Coupland 
et al.
SK‑N‑F1 cells Incubation of cells with 
vitamin E
0.50 and 100 mM vitamin E. Protective effect against PD by 
increasing MAPT methylation.
Molina  
et al.  
34 PD patients and 
47 healthy individuals 
Vitamin E levels in serum 
and cerebrospinal fluid 
Vitamin E levels in the serum 
and cerebrospinal fluid were 
compared between the groups.
There was no correlation between PD 
prognosis and vitamin E levels in the 





2,000 IU/day vitamin E 
supplementation 
Vitamin E supplementation was 
given before levodopa use. 
Vitamin E supplementation did not 
affect the frequency of side effects that 
may arise due to levodopa use.
Fukushima 
et al.  
82 PD patients and 
82 healthy individuals 
Serum vitamin E 
and copper level 
Serum vitamin E and copper 
levels were compared between 
the groups.
Serum vitamin E/copper ratio and 
serum E vitamin levels were not 
different between the groups (p>0.05).
Paraskevas 
et al.  
72 PD patients and 
39 healthy individuals 
Serum vitamin E level 
 
Serum vitamin E levels were 
compared between the groups. 
Serum vitamin E levels in patients with 
vascular parkinsonism were found to 
be lower than some groups (p<0.05).
Kim  
et al.
104 PD patients and 
52 healthy individuals
Serum vitamin E level Serum vitamin E levels were 
compared between the groups.
Serum vitamin E levels were not 
different between the groups (p>0.05).
Tohgi  
et al.  
 
14 treatment‑naive PD 
patients, 8 PD patients 





α‑tocopherol levels in the 
cerebrospinal fluid were 
compared between the groups. 
α‑tocopherol concentrations in 
treatment‑naive PD patients were lower 
than the control group (p<0.001). 
Dexter  
et al.  
12 PD patients and 
12 healthy individuals 
α‑tocopherol 
concentrations in brain 
tissues
α‑tocopherol concentrations in 
brain tissues were compared 
between groups.
No difference was observed among 
the groups (p>0.05). 
Yang et al.  
 
 
38,937 female and 
45,837 male participants 
 
Dietary vitamin E, vitamin 
C and β‑carotene intakes 
and total antioxidant 
capacity of participants
The correlation between PD 
and consumption of these 
vitamins was examined. 
PD risk and dietary vitamin E and 
β‑carotene intake were found to have 
a negative correlation (p<0.05). 
Hughes 
et al.  
1,036 PD patients 
 
Dietary antioxidant 
vitamin intakes were 
evaluated in the patients
The correlation between PD 
and dietary antioxidant vitamin 
intake was examined.
There was no correlation between PD 
and dietary vitamin E intake (p>0.05). 
Miyake 
et al.  
249 PD patients and 
368 healthy participants 
Nutritional status and 
food consumption were 
evaluated in the patients
The correlation between PD 
and dietary nutrition intake 
was examined.
Dietary vitamin intake in high amounts 
decreased PD risk (p<0.05). 
Scheider 
et al.  
 
57 PD patients and 
50 healthy participants 
 
Consumption of 102 foods 
considered to be rich 
in vitamins E and C was 
evaluated
Correlation of dietary vitamin 
E and C intake with PD 
was examined. 
There was no statistically significant 
correlation between PD and dietary 
vitamin E intake (p>0.05). 
Taghizadeh 











Placebo was given to 
30 patients and 400 IU 
vitamin E supplementation 
+ 1,000 mg n‑3 fatty acids 
supplementation was 
given to the other 30 
patients for 12 weeks
Unified PD rating stage (UPDRS) 
scores of patients were 




Better increases in UPDRS scores were 
observed in the intervention group 





et al.  
54 PD patients and 
93 healthy individuals 
Serum vitamin E levels 
 
Serum vitamin E levels in the 
groups were compared and 
evaluated.
There was no significant correlation 
between PD and serum vitamin E levels 
(p>0.05). 
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Studies related to stroke and vitamin E 
In a large study by Voko et al. (2003) 5,197 individ‑
uals with no cognitive impairment were tracked by 
means of food consumption frequency for approxi‑
mately 6.4 years. It was found that dietary vitamin E 
intake protects against ischemic stroke in smokers. 
The failure to reach the same result in other individu‑
als could be associated with the fact that the study was 
conducted in the general population, not on individ‑
uals with high cerebrovascular risk. In another study 
that included 41,620 male and female participants, 
there was a positive correlation between dietary vita‑
min E intake and hemorrhagic stroke. The reason of 
this unexpected result could be explained by the anti‑
platelet and anticoagulant effects of vitamin E (Del Rio 
et al., 2010). A study conducted among 80,244 individ‑
uals between 45 and 74 years of age in Japan demon‑
strated that dietary α‑tocopherol intake decreased the 
risk of all stroke types, including ischemic stroke (Ue‑
sugi et al., 2017). According to results of a meta‑anal‑
ysis study, dietary vitamin E intake in high amounts 
was found to be correlated with low stroke risk. Since 
vitamin E is a lipid soluble antioxidant that has the 
ability to sequester ROS, it might improve atheroscle‑
rotic plaque stability. In addition, vitamin E can inhibit 
platelet aggregation and thrombus formation (Cheng 
et al., 2018). 
In another study, individuals 50–69 years old taking 
50 mg α‑tocopherol supplementation were tracked for 
approximately six years. Results of the study revealed 
that vitamin E increases stroke risk in hypertensive 
individuals. This may be because vitamin E may have 
increased bleeding risk because it acts synergistical‑
ly with the blood diluent effect of aspirin (Leppälä et 
al., 2000). In a study conducted in rats, supplemen‑
tation at a dose of 44 mg/kg body weight (2,600 mg/
human/day‑equivalent) increased blood pressure and 
showed side effects in the CNS of hypertensive rats 
with stroke risk. The study stated that α‑tocopherol 
supplementation leads to impairments in the CNS in 
rats (Miyamoto et al., 2009). Another study supports 
these findings. Supplementation of α‑tocopherol in 
high amounts (its equivalent in humans is 1,860 IU) 
increased neuro‑inflammatory indicators in rats af‑
ter stroke. This finding can be attributed to increased 
microglial activation and oxidative stress in the rats 
(Khanna et al., 2014). In another study, serum α‑to‑
copherol levels in male smokers were found to be cor‑
related with low ischemic risk (Leppälä et al., 1999). In 
line with these data, it can be concluded that in gen‑
eral, dietary vitamin E intake may decrease the risk of 
stroke. However, vitamin E supplementation in stroke 
patients is controversial as it has side effects. For this 
reason, supplementation should not be recommended 
for stroke patients and dietary intake should not ex‑
ceed recommended levels.
Multi‑effects and mechanisms of vitamin E  
on amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis 
ALS was defined by the French neurologist Charcot 
as a neurodegenerative disease which affects upper and 
lower motor neurons (Oskarsson et al., 2018). The aver‑
age onset of ALS is between 58 and 60 years of age and 
the incidence is around two per 100,000 persons (Gun‑
narsson and Bodin, 2018). However, during the seventh 
decade of life in the US, the incidence increases to five 
cases per 100,000. Although the pathogenesis of ALS is 
not completely known, ALS‑related neuropathologic 
features and gene mutations have been shown to sig‑
nificantly add to the etiology of the disease (Oskarsson 
et al., 2018). 
Potential mechanisms of amyotrophic lateral sclerosis 
An increase in the levels of oxidative damage bio‑
markers in ALS patients indicates that oxidative stress 
plays important roles in the pathogenesis of the dis‑
ease (Bonnefont‑Rousselot et al., 2000; Barber and 
Shaw, 2010). Additionally, mutations in the copper/
zinc superoxide dismutase gene (SOD1), which is vital 
in antioxidant defense mechanisms, were reported in 
some ALS patients (Rosen et al., 1993). Mutations in 
this gene may cause oxidative damage by increasing 
levels of hydroxyl radicals (Wiedau‑Pazos et al., 1996; 
Bogdanov et al., 1998). Other pathogenic mechanisms 
of ALS, other than oxidative stress, include the accu‑
mulation of misfolded proteins, mitochondrial dys‑
function, neuroinflammation, apoptosis and increased 
cellular glutamate concentrations (Spreux‑Varoquaux 
et al., 2002; Bendotti and Carrì, 2004; Brooks et al., 
2004; Vijayvergiya et al., 2005, Kiaei et al., 2006; Patel 
and Hamadeh, 2009). 
Vitamin E in amyotrophic lateral sclerosis 
Different treatment methods are being examined 
in the prevention ALS and/or improving its progno‑
sis. Medical nutrition therapy is a potential treat‑
ment being investigated for ALS (Patel and Hamadeh, 
2009). In studies, ALS has been positively correlated 
with glutamate (Nelson et al., 2000), fat (Sienko et al., 
1990), fish and milk consumption (Felmus et al., 1976; 
Pierce‑Ruhland and Patten, 1981), while negatively 
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correlated with lycopene (Longnecker et al., 2000) and 
dietary fiber intake (Nelson et al., 2000). Besides these 
nutrients, antioxidant vitamin supplements were also 
shown to be important in nutrition therapy (Patel and 
Hamadeh, 2009). Studies that examined the correla‑
tion between ALS risk and dietary antioxidant vita‑
min intake mostly focused on vitamin E (Ascherio et 
al., 2005; Veldink et al., 2007). These studies suggest 
that dietary vitamin E supplementation and increased 
cerebrospinal α‑tocopherol levels decrease oxidative 
stress by reducing the risk of de novo mutation that 
may occur in the SOD1 gene, and this mechanism can 
decrease neuron degeneration and ALS risk (Hideo et 
al., 1996). Additionally, vitamin E may reduce progres‑
sion of ALS and neuronal damage by decreasing the 
peroxidation of lipids and nutritional polyunsaturat‑
ed fatty acids (Veldink et al., 2007; Asl et al., 2018). 
4‑Hydroxynonenal, a product of lipid peroxidation, is 
reported to increase ALS risk by contributing to gluta‑
mate excitotoxicity (Pedersen et al., 1998). 
Studies on vitamin E in amyotrophic lateral sclerosis 
It has been reported that vitamin E decelerates the 
clinical course of ALS in rats with mutations in the 
Sod1 gene (Gurney et al., 1996). A study evaluating the 
correlation between dietary nutrient intake and ALS 
indicated that dietary vitamin E intake decreased the 
progression risk of ALS (Veldink et al., 2007). Anoth‑
er study showed that vitamin E supplementation de‑
creases the risk of death risk in ALS patients. In ad‑
dition, other vitamin supplementations did not have 
the same inverse correlation (Ascherio et al., 2005). 
Another study found that supplementation of vitamin 
E at a dose of 500 mg/day for three months decreased 
levels of oxidative stress biomarkers in plasma (Desnu‑
elle et al., 2001). However, studies evaluating the effect 
of supplementation of vitamin E at doses of 600 mg/
day (Galbussera et al., 2006) and 5,000 mg/day (Graf et 
al., 2005) in ALS patients determined that supplemen‑
tation does not have a statistically significant effect on 
the progression of the disease and life quality of pa‑
tients. In light of these data, it can be concluded that 
vitamin E supplementation may have important pro‑
tective roles in ALS and its prognosis. However, before 
adopting vitamin E as a viable treatment option, deter‑
mining the effective dose and further human studies 
are required. 
Increased serum levels of α‑tocopherol have been 
correlated with low ALS risk (Freedman et al., 2013), 
and another study showed that α‑tocopherol levels 
in the cerebrospinal fluid of ALS patients were lower 
than in healthy individuals (Hideo et al., 1996). How‑
ever, other studies could not find such a correlation 
between serum levels of vitamin E and ALS risk (Iwa‑
saki et al., 1995), or changes in α‑tocopherol levels 
in cerebrospinal fluid and serum in ALS patients (De 
Bustos et al., 1998). Due to such contradictory results, 
it is required to conduct further studies examining 
vitamin E levels in serum and cerebrospinal fluids of 
ALS patients. 
CONCLUSION 
The effect of vitamin E, a strong antioxidant, on 
neurodegenerative diseases has been long under in‑
vestigation. Generally, it can be concluded that dietary 
vitamin E and its intake as a supplement may decrease 
the risk of PD and ALS; however, in some studies, cor‑
relations have not been observed between these dis‑
eases and vitamin E levels in the serum and cerebro‑
spinal fluid. It has been found that serum and/or plas‑
ma vitamin E levels in AD patients were quite low, and 
high serum and dietary levels are protective against 
the disease. Therefore, it is important to track serum 
and/or plasma vitamin E levels constantly in disease 
progression. 
Vitamin E supplementation in stroke patients is 
controversial as it has side effects. It was found that 
supplementation at very high doses increases stroke 
risk by scaling up hemorrhage risk. The effects of di‑
etary vitamin E on stroke risk are very inconsistent. For 
this reason, supplementation is not recommended for 
stroke patients and dietary intake should not exceed 
recommended levels. 
In light of these data, vitamin E supplementation 
may be taken into consideration depending on the type 
of disease in order to prevent risk and/or the progres‑
sion of neurodegenerative diseases. However, further 
studies are required to determine therapeutic doses 
in humans.
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